Alberta Adds ELIDEL® Cream to Public Drug Plan for Atopic Dermatitis
Event summary
- Alberta's public drug plan now reimburses ELIDEL® (pimecrolimus) cream for eligible patients with mild to moderate atopic dermatitis.
- The addition follows existing coverage in British Columbia, Saskatchewan, Ontario, and Québec.
- ELIDEL® has been available by prescription in Canada since 2003 and is indicated as a second-line therapy.
- Clinical trials show ELIDEL® significantly improves symptoms compared to vehicle treatments.
The big picture
Bausch Health's inclusion of ELIDEL® in Alberta's public drug plan broadens access to a non-corticosteroid treatment for atopic dermatitis, aligning with trends toward expanded coverage for chronic skin conditions. This strategic win could enhance patient outcomes and strengthen Bausch Health's position in the dermatology market, particularly as more provinces consider similar reimbursement policies.
What we're watching
- Market Expansion
- Whether Bausch Health can leverage this reimbursement to expand ELIDEL®'s market share in Canada.
- Regulatory Dynamics
- The pace at which other provinces may follow Alberta's lead in covering ELIDEL® under public drug plans.
- Competitive Positioning
- How this move affects Bausch Health's competitive stance against other dermatology treatments.
Related topics